Novavax, Inc.
NVAX
$5.96
-$0.23-3.72%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.25B | 682.16M | 885.19M | 987.67M | 996.61M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.25B | 682.16M | 885.19M | 987.67M | 996.61M |
| Cost of Revenue | 522.40M | 569.64M | 728.52M | 786.30M | 905.96M |
| Gross Profit | 732.56M | 112.52M | 156.67M | 201.37M | 90.65M |
| SG&A Expenses | 288.88M | 323.59M | 405.48M | 445.99M | 427.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 832.15M | 914.09M | 1.18B | 1.27B | 1.37B |
| Operating Income | 422.81M | -231.93M | -290.02M | -285.83M | -377.77M |
| Income Before Tax | 488.52M | -176.62M | -279.74M | -288.88M | -395.60M |
| Income Tax Expenses | 9.82M | 10.88M | 5.12M | 5.46M | 3.11M |
| Earnings from Continuing Operations | 478.70 | -187.50 | -284.86 | -294.33 | -398.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 478.70M | -187.50M | -284.86M | -294.33M | -398.71M |
| EBIT | 422.81M | -231.93M | -290.02M | -285.83M | -377.77M |
| EBITDA | 467.50M | -183.44M | -243.25M | -240.44M | -333.45M |
| EPS Basic | 3.05 | -1.22 | -2.16 | -2.67 | -3.11 |
| Normalized Basic EPS | 1.79 | -0.85 | -1.28 | -1.61 | -1.80 |
| EPS Diluted | 2.67 | -1.32 | -2.26 | -2.77 | -3.18 |
| Normalized Diluted EPS | 1.53 | -0.93 | -1.35 | -1.68 | -1.87 |
| Average Basic Shares Outstanding | 629.72M | 608.59M | 572.02M | 515.40M | 456.39M |
| Average Diluted Shares Outstanding | 663.77M | 626.06M | 589.50M | 532.88M | 471.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |